Cancer Center Support Grant

项目总结(见说明)： 新泽西州癌症研究所(CINJ)作为新泽西州唯一指定的国家癌症研究所(NCI)指定的综合癌症中心，以满足我国最多样化和人口最稠密的州之一的癌症研究需求。作为一个矩阵和联盟的癌症中心，自1997年以来一直由NCI CCSG机制资助，CINJ开展最先进的研究、患者护理和外展/教育。CINJ目前由来自32个学术部门的161名成员组成，他们拥有超过9,290万美元的同行评议支持，6,110万美元的年度直接支持，2,890万美元的NCI支持和1,870万美元的年度直接NCI支持(自2004年上次提交以来，NCI支持增加了20%)。 自2008年9月罗伯特·S·迪保拉博士被任命为中心主任以来，研究人员发起的临床治疗试验的收益增加了一倍多；在基础科学、临床科学、公共卫生科学和系统生物学/生物信息学等多个领域招聘了17名新教师； 与普林斯顿大学和罗格斯大学的关系得到加强和正规化；该州的癌症登记和SEER合同被转移到CINJ；又启动了四次招聘搜索。CINJ现在有六个既定的研究项目：细胞死亡和生存信号；基因组不稳定和肿瘤 发展；癌症药理学和临床前治疗；临床研究；癌症发生和化学预防；以及癌症预防和控制。CINJ支持14个共享资源，包括：流式细胞术和细胞分选；功能基因组学；转基因和基因敲除小鼠；药代动力学和 药效学；组织病理学和成像；生物资料库服务；生物信息学；生物计量学；研究药学；人类研究服务办公室；临床研究人员的集中教育和培训； 小动物成像(发展中)、代谢组学(发展中)和流行病学服务(发展中)。总体而言，CINJ在NCI指定的中心中具有独特的利基地位，因为它受益于作为母体癌症中心的机会，同时在大学母体之外拥有全州范围的权威，从而建立了一个环境，以促进和正式形成大学母体内外的跨学科和转化性研究愿景。 我们请求CCSG在高级领导、计划领导、规划和评估、发展资金、管理、共享资源、协议审查和监测、协议特定研究支持以及数据和安全监测方面提供支持。

PROJECT SUMMARY (See instructions): The Cancer Institute of New Jersey (CINJ) prevails, as the State of New Jersey's only National Cancer Institute (NCI)-designated Comprehensive Cancer Center, to satisfy the cancer research demands of one of the most diverse and densely populated States in our Nation. As a matrix and consortium cancer center that has been continuously funded by the NCI CCSG mechanism since 1997, CINJ conducts state of the art research, patient care, and outreach/education. CINJ is currently comprised of 161 members from a total of 32 academic departments who hold over $92.9 million total peer-reviewed support, $61.1 million annual direct support, $28.9 million total NCI support and $18.7 million annual direct NCI support (a 20% Increase in NCI support since the time ofthe last submission in 2004). Since the appointment of Dr. Robert S. DiPaola as center director in September, 2008, accrual onto investigator initiated therapeutic clinical trials has more than doubled; 17 new faculty were recruited in multiple areas including Basic Science, Clinical Science, Public Health Science, and Systems Biology/Bioinformatics; the Consortium relationship with Princeton University and Rutgers University was strengthened and formalized; the State's cancer registry and SEER contract was moved to CINJ; and an additional four recruitment searches were launched. CINJ now has six established Research Programs: Cell Death and Survival Signaling; Genomic Instability and Tumor Growth; Cancer Pharmacology and Preclinical Therapeutics; Clinical Investigations; Carcinogenesis and Chemoprevention; and Cancer Prevention and Control. CINJ supports 14 Shared Resources, including: Flow Cytometry and Cell Sorting; Functional Genomics; Transgenic and Knockout Mouse; Pharmacokinetics and Pharmacodynamics; Histopathology and Imaging; Biorepository Service; Bioinformatics; Biometrics; Research Pharmacy; Office of Human Research Services; Centralized Education and Training for Clinical Research Personnel; Small Animal Imaging (developing); Metabolomics (developing) and Epidemiology Services (developing). Overall, CINJ has a unique niche among NCI-designated centers, as it benefits from opportunities as a matrix cancer center and at the same time has State-wide authority beyond the University matrix, thus establishing an environment to foster and formalize a Vision of Transdisciplinary and Translational Research within and beyond the University matrix. We are requesting CCSG support for Senior leadership, Program Leadership, Planning and Evaluation, Developmental Funds, Administration, Shared Resources, Protocol Review and Monitoring, Protocol Specific Research Support, and Data and Safety Monitoring.